All In Biotech

Drug Trial Radar · NCT04234607

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

A Randomized, Double-blind, Controlled, Multicenter Phase III Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 738 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

738

Planned (sponsor's estimate)

Start

Jan 2020

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Sponsor type
Industry
First posted
Jan 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in subjects with extensive small cell lung cancer. The primary outcome measures include PFS and OS. Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the informed consent, and then centrally randomized 1:1:1 to the experimental arms and the control arm.

Conditions

  • Extensive Small Cell Lung Cancer

Interventions

  • TQB2450Drug

    TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • AnlotinibDrug

    a multi-target receptor tyrosine kinase inhibitor

  • EtoposideDrug

    Etoposide is a cell cycle-specific antitumor drug

  • CarboplatinDrug

    Carboplatin is cell cycle nonspecific antitumor drug

  • TQB2450(blank)Drug

    Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day

  • Anlotinib(blank)Drug

    Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: up to 12 months
  2. Overall survival (OS)Time frame: up to 24 months

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Anhui chest hospital

    Hefei, Anhui, China

  • AnHui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing chest hospital,capital medical university

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Fiest Affiliated Hospital of Guanghzou University of Chinese Medicine

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • Guizhou Provincial people's Hospital

    Guiyang, Guizhou, China

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • Shijiazhuang First Hospital

    Shijiazhuang, Hebei, China

  • Hebei Chest Hospital

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Jinzhou Central Hospital

    Jinzhou, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First People's Hospital of Lianyungang

    Lianyungang, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.